IP Library Granted Patent US 8,785,411
Granted Patent B2
US 8,785,411 · App. 13/185,158 · Granted Jul 22, 2014

HIV DNA vaccine methods of use

Inventors: Opendra Narayan (Lenexa, KS); Zhenqian Liu (Lenexa, KS)
Assignee: University of Kansas Medical Center
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,785,411
App. No.
13/185,158
Granted
Jul 22, 2014
Kind
B2
Abstract

The present invention is directed to a DNA vaccine for immunization against HIV. The invention comprises a DNA molecule that has a sequence encoding a plurality of viral proteins capable of stimulating an immune response against HIV. The DNA molecule is rendered safe for use as a vaccine by the disruption of genes encoding reverse transcriptase, integrase, and Vif. The DNA molecule is further rendered safe by at least a partial deletion of the 3′ LTR.

Claims (7)

1. A method of stimulating an immune response in a recipient against Human Immunodeficiency Virus (HIV) comprising: administering to the recipient a DNA composition comprising a promoter sequence operably linked to a coding sequence, wherein the coding sequence encodes a gag gene of Human Immunodeficiency Virus (HIV), a pro gene of HIV, a vpx gene of Simian Immunodeficiency Virus (SIV), a vpr gene of SIV, a vpu gene of HIV, a nef gene of HIV, a tat gene of HIV, an env gene of HIV, and a rev gene of HIV, with the coding sequence operably linked to a polyadenylation sequence, and wherein the DNA composition does not include functional reverse transcriptase (rt), integrase (int), and viral infectivity factor (vif) genes.

2. The method of claim 1 , wherein the coding sequence encodes at least one non-functional gene.

3. The method of claim 1 , wherein the promoter sequence is a 5′ long terminal repeat (LTR) of SIV.

4. The method of claim 1 , wherein the polyadenylation sequence is an SV40 polyadenylation sequence.

5. The method of claim 1 , wherein the DNA composition is in a pharmaceutically acceptable carrier.

6. The method of claim 1 further comprising administering to the recipient at least one cytokine.

7. The method of claim 1 , further comprising administering to the recipient at least one anti-viral drug therapy.

Continuity (3)
Continuation 10941164 · Sep 15, 2004
Provisional Application 60503194 · Sep 15, 2003
Related Publication 20120021000A1 · Jan 26, 2012